全文获取类型
收费全文 | 264篇 |
免费 | 21篇 |
国内免费 | 2篇 |
专业分类
耳鼻咽喉 | 4篇 |
儿科学 | 11篇 |
妇产科学 | 8篇 |
基础医学 | 30篇 |
口腔科学 | 1篇 |
临床医学 | 8篇 |
内科学 | 45篇 |
皮肤病学 | 1篇 |
神经病学 | 20篇 |
特种医学 | 5篇 |
外科学 | 33篇 |
综合类 | 3篇 |
预防医学 | 72篇 |
眼科学 | 2篇 |
药学 | 19篇 |
肿瘤学 | 25篇 |
出版年
2023年 | 2篇 |
2022年 | 3篇 |
2021年 | 6篇 |
2020年 | 7篇 |
2019年 | 1篇 |
2018年 | 3篇 |
2017年 | 9篇 |
2016年 | 7篇 |
2015年 | 3篇 |
2014年 | 15篇 |
2013年 | 8篇 |
2012年 | 16篇 |
2011年 | 20篇 |
2010年 | 3篇 |
2009年 | 11篇 |
2008年 | 10篇 |
2007年 | 12篇 |
2006年 | 9篇 |
2005年 | 8篇 |
2004年 | 11篇 |
2003年 | 14篇 |
2002年 | 7篇 |
2001年 | 3篇 |
2000年 | 10篇 |
1999年 | 8篇 |
1998年 | 3篇 |
1997年 | 1篇 |
1996年 | 2篇 |
1995年 | 1篇 |
1994年 | 5篇 |
1993年 | 4篇 |
1992年 | 13篇 |
1991年 | 11篇 |
1990年 | 12篇 |
1989年 | 7篇 |
1988年 | 3篇 |
1987年 | 2篇 |
1986年 | 6篇 |
1985年 | 3篇 |
1978年 | 1篇 |
1972年 | 2篇 |
1968年 | 1篇 |
1967年 | 1篇 |
1946年 | 1篇 |
1935年 | 2篇 |
排序方式: 共有287条查询结果,搜索用时 31 毫秒
1.
2.
Preclinical evaluation of a novel CEA‐targeting near‐infrared fluorescent tracer delineating colorectal and pancreatic tumors 下载免费PDF全文
Martin C. Boonstra Berend Tolner Boudewijn E. Schaafsma Leonora S.F. Boogerd Hendrica A.J.M Prevoo Guarav Bhavsar Peter J.K. Kuppen Cornelis F.M. Sier Bert A. Bonsing John V. Frangioni Cornelis J.H. van de Velde Kerry A. Chester Alexander L. Vahrmeijer 《International journal of cancer. Journal international du cancer》2015,137(8):1910-1920
Surgery is the cornerstone of oncologic therapy with curative intent. However, identification of tumor cells in the resection margins is difficult, resulting in nonradical resections, increased cancer recurrence and subsequent decreased patient survival. Novel imaging techniques that aid in demarcating tumor margins during surgery are needed. Overexpression of carcinoembryonic antigen (CEA) is found in the majority of gastrointestinal carcinomas, including colorectal and pancreas. We developed ssSM3E/800CW, a novel CEA‐targeted near‐infrared fluorescent (NIRF) tracer, based on a disulfide‐stabilized single‐chain antibody fragment (ssScFv), to visualize colorectal and pancreatic tumors in a clinically translatable setting. The applicability of the tracer was tested for cell and tissue binding characteristics and dosing using immunohistochemistry, flow cytometry, cell‐based plate assays and orthotopic colorectal (HT‐29, well differentiated) and pancreatic (BXPC‐3, poorly differentiated) xenogeneic human–mouse models. NIRF signals were visualized using the clinically compatible FLARE? imaging system. Calculated clinically relevant doses of ssSM3E/800CW selectively accumulated in colorectal and pancreatic tumors/cells, with highest tumor‐to‐background ratios of 5.1 ± 0.6 at 72 hr postinjection, which proved suitable for intraoperative detection and delineation of tumor boarders and small (residual) tumor nodules in mice, between 8 and 96 hr postinjection. Ex vivo fluorescence imaging and pathologic examination confirmed tumor specificity and the distribution of the tracer. Our results indicate that ssSM3E/800CW shows promise as a diagnostic tool to recognize colorectal and pancreatic cancers for fluorescent‐guided surgery applications. If successfully translated clinically, this tracer could help improve the completeness of surgery and thus survival. 相似文献
3.
4.
Fayers PM Palumbo A Hulin C Waage A Wijermans P Beksaç M Bringhen S Mary JY Gimsing P Termorshuizen F Haznedar R Caravita T Moreau P Turesson I Musto P Benboubker L Schaafsma M Sonneveld P Facon T;Nordic Myeloma Study Group;Italian Multiple Myeloma Network;Turkish Myeloma Study Group;Hemato-Oncologie voor Volwassenen Nederland;Intergroupe Francophone du Myélome;European Myeloma Network 《Blood》2011,118(5):1239-1247
The role of thalidomide for previously untreated elderly patients with multiple myeloma remains unclear. Six randomized controlled trials, launched in or after 2000, compared melphalan and prednisone alone (MP) and with thalidomide (MPT). The effect on overall survival (OS) varied across trials. We carried out a meta-analysis of the 1685 individual patients in these trials. The primary endpoint was OS, and progression-free survival (PFS) and 1-year response rates were secondary endpoints. There was a highly significant benefit to OS from adding thalidomide to MP (hazard ratio = 0.83; 95% confidence interval 0.73-0.94, P = .004), representing increased median OS time of 6.6 months, from 32.7 months (MP) to 39.3 months (MPT). The thalidomide regimen was also associated with superior PFS (hazard ratio = 0.68, 95% confidence interval 0.61-0.76, P < .0001) and better 1-year response rates (partial response or better was 59% on MPT and 37% on MP). Although the trials differed in terms of patient baseline characteristics and thalidomide regimens, there was no evidence that treatment affected OS differently according to levels of the prognostic factors. We conclude that thalidomide added to MP improves OS and PFS in previously untreated elderly patients with multiple myeloma, extending the median survival time by on average 20%. 相似文献
5.
M. A. ElTanbouly E. Schaafsma R. J. Noelle J. L. Lines 《Clinical and experimental immunology》2020,200(2):120-130
The immune response is governed by a highly complex set of interactions among cells and mediators. T cells may be rendered dysfunctional by the presence of high levels of antigen in the absence of co-stimulation while myeloid cells may be programmed towards an immunosuppressive state that promotes cancer growth and metastasis while deterring tumor immunity. In addition, inhibitory programs driven by immune checkpoint regulators dampen anti-tumor immunity. The ideal cancer immunotherapy treatment will improve both cross-priming in the tumor microenvironment and relieve suppression by the inhibitory checkpoints. Recently, blockade of programmed cell death 1 (PD-1) and cytotoxic T lymphocyte antigen 4 (CTLA-4) has elicited impressive results, but not in all patients, so additional targets are under investigation. V-set immunoglobulin domain suppressor of T cell activation (VISTA) is a novel immunoregulatory receptor that is broadly expressed on cells of the myeloid and lymphoid lineages, and is frequently implicated as a poor prognostic indicator in multiple cancers. Importantly, antibody targeting of VISTA uniquely engages both innate and adaptive immunity. This, combined with the expression of VISTA and its non-redundant activities compared to other immune checkpoint regulators, qualifies VISTA to be a promising target for improving cancer immunotherapy. 相似文献
6.
Genomic array as compared to karyotyping in myelodysplastic syndromes in a prospective clinical trial 下载免费PDF全文
Marian J. Stevens‐Kroef Daniel Olde Weghuis Najat ElIdrissi‐Zaynoun Bert van der Reijden Eline M. P. Cremers Canan Alhan Theresia M. Westers Heleen A. Visser‐Wisselaar Dana A. Chitu Sonia M. Cunha Edo Vellenga Saskia K. Klein Pierre Wijermans Georgine E. de Greef M. Ron Schaafsma Petra Muus Gert J. Ossenkoppele Arjan A. van de Loosdrecht Joop H. Jansen 《Genes, chromosomes & cancer》2017,56(7):524-534
Karyotyping is considered as the gold standard in the genetic subclassification of myelodysplastic syndrome (MDS). Oligo/SNP‐based genomic array profiling is a high‐resolution tool that also enables genome wide analysis. We compared karyotyping with oligo/SNP‐based array profiling in 104 MDS patients from the HOVON‐89 study. Oligo/SNP‐array identified all cytogenetically defined genomic lesions, except for subclones in two cases and balanced translocations in three cases. Conversely, oligo/SNP‐based genomic array profiling had a higher success rate, showing 55 abnormal cases, while an abnormal karyotype was found in only 35 patients. In nine patients whose karyotyping was unsuccessful because of insufficient metaphases or failure, oligo/SNP‐based array analysis was successful. Based on cytogenetic visible abnormalities as identified by oligo/SNP‐based genomic array prognostic scores based on IPSS/‐R were assigned. These prognostic scores were identical to the IPSS/‐R scores as obtained with karyotyping in 95%‐96% of the patients. In addition to the detection of cytogenetically defined lesions, oligo/SNP‐based genomic profiling identified focal copy number abnormalities or regions of copy neutral loss of heterozygosity that were out of the scope of karyotyping and fluorescence in situ hybridization. Of interest, in 26 patients we demonstrated such cytogenetic invisible abnormalities. These abnormalities often involved regions that are recurrently affected in hematological malignancies, and may therefore be of clinical relevance. Our findings indicate that oligo/SNP‐based genomic array can be used to identify the vast majority of recurrent cytogenetic abnormalities in MDS. Furthermore, oligo/SNP‐based array profiling yields additional genetic abnormalities that may be of clinical importance. 相似文献
7.
8.
9.
10.